The overexpression of NCL frequently occurs in cancers [25, 26] and is positively correlated with worse clinical outcomes [28], which is consistent with our discoveries that leukemia patients with higher NCL levels have shorter survival than those with lower NCL expression. Here, NUCLEOLIN is linked to cancer.